Cargando…
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
Autores principales: | Law, Ernest H, Cameron, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402903/ https://www.ncbi.nlm.nih.gov/pubmed/37114409 http://dx.doi.org/10.57264/cer-2023-0009 |
Ejemplares similares
-
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023) -
Reply to the Letter
por: Kim, H., et al.
Publicado: (2015) -
Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Bruce, Ian N, et al.
Publicado: (2022) -
Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020) -
Reply to the Letter “Create Guidelines for Characterization of Venom Peptides” from Dr. Volker Herzig
por: Gomez, Marcus Vinicius
Publicado: (2016)